# Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study

> **NCT07514052** · — · RECRUITING · sponsor: **Shanxi Bethune Hospital** · enrollment: 127 (estimated)

## Conditions studied

- Multiple Myeloma of Bone

## Interventions

- **DRUG:** Selinexor-Based Regimen

## Key facts

- **NCT ID:** NCT07514052
- **Lead sponsor:** Shanxi Bethune Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-04-30
- **Target enrollment:** 127 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07514052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07514052, "Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07514052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*